DK1330455T3 - Hidtil ukendte 7-azaindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling - Google Patents

Hidtil ukendte 7-azaindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling

Info

Publication number
DK1330455T3
DK1330455T3 DK01988718T DK01988718T DK1330455T3 DK 1330455 T3 DK1330455 T3 DK 1330455T3 DK 01988718 T DK01988718 T DK 01988718T DK 01988718 T DK01988718 T DK 01988718T DK 1330455 T3 DK1330455 T3 DK 1330455T3
Authority
DK
Denmark
Prior art keywords
azaindoles
phosphodiesterase
inhibitors
preparation
new
Prior art date
Application number
DK01988718T
Other languages
Danish (da)
English (en)
Inventor
Norbert Hoefgen
Ute Egerland
Thomas Kronbach
Degenhard Marx
Stefan Szelenyi
Hildegard Kuss
Emmanuel Polymeropoulos
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10053275A external-priority patent/DE10053275A1/de
Application filed by Elbion Ag filed Critical Elbion Ag
Application granted granted Critical
Publication of DK1330455T3 publication Critical patent/DK1330455T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
DK01988718T 2000-10-27 2001-10-25 Hidtil ukendte 7-azaindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling DK1330455T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10053275A DE10053275A1 (de) 2000-10-27 2000-10-27 Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
US24434200P 2000-10-30 2000-10-30

Publications (1)

Publication Number Publication Date
DK1330455T3 true DK1330455T3 (da) 2005-12-05

Family

ID=26007507

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01988718T DK1330455T3 (da) 2000-10-27 2001-10-25 Hidtil ukendte 7-azaindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling

Country Status (27)

Country Link
US (3) US7169787B2 (cs)
EP (1) EP1330455B1 (cs)
JP (1) JP4233322B2 (cs)
KR (2) KR100837099B1 (cs)
CN (1) CN1247576C (cs)
AR (1) AR034269A1 (cs)
AT (1) ATE301121T1 (cs)
AU (2) AU2175302A (cs)
BG (1) BG66169B1 (cs)
BR (1) BR0114903A (cs)
CA (1) CA2428468C (cs)
CZ (1) CZ20031146A3 (cs)
DE (1) DE50106993D1 (cs)
DK (1) DK1330455T3 (cs)
EE (1) EE05271B1 (cs)
ES (1) ES2246349T3 (cs)
HR (1) HRP20030427B1 (cs)
HU (1) HUP0303034A3 (cs)
IL (2) IL155386A0 (cs)
MX (1) MXPA03003624A (cs)
NO (1) NO324947B1 (cs)
NZ (1) NZ525369A (cs)
PL (1) PL213999B1 (cs)
PT (1) PT1330455E (cs)
SK (1) SK287774B6 (cs)
TW (1) TWI262920B (cs)
WO (1) WO2002034747A1 (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
KR20090048520A (ko) * 2002-11-06 2009-05-13 셀진 코포레이션 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨 억제 약물의 사용 방법 및 그 조성물
DE10318610A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US20050054691A1 (en) * 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Carboxylesterase inhibitors
MXPA06002853A (es) * 2003-09-11 2006-06-14 Kemia Inc Inhibidores citoquina.
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン,インコーポレーテッド Pde4b阻害剤及びその使用
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
EP1786813A2 (en) * 2004-09-03 2007-05-23 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
AU2007254179B2 (en) 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
US8252774B2 (en) * 2008-09-22 2012-08-28 Isis Innovation Ltd. 5-azaindole bisphosphonates
US8816085B2 (en) * 2009-08-26 2014-08-26 Takeda Gmbh Methylpyrrolopyridinecarboxamides
WO2012072727A1 (en) 2010-12-03 2012-06-07 Biotie Therapies Gmbh Crystalline modification of n-(3,5-dichloropyridin-4-yl)-[1-(4 -fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide as inhibitor of pde4
WO2012080329A1 (en) 2010-12-17 2012-06-21 Biotie Therapies Gmbh Formulations of n-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide
CN102584842A (zh) * 2011-01-17 2012-07-18 北京大学 取代吲哚并内酰胺衍生物的制备及作为抗疟疾剂的用途
DK2888010T3 (da) 2012-08-22 2021-06-28 Univ Cornell Fremgangsmåder til at hæmme fascin
WO2015127125A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
ES2987854T3 (es) 2018-10-12 2024-11-18 Board Of Regents Of Theuniversity Of Nebraska Inhibidores de fosfodiesterasa
US12459938B2 (en) 2019-03-04 2025-11-04 Beth Israel Deaconess Medical Center, Inc. ORAI channel inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
FI922347L (fi) 1990-01-05 1992-05-22 Pfizer Azaoxindolderivat.
US5023265A (en) 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5811432A (en) 1990-11-09 1998-09-22 Pfizer Inc Azaoxindole derivatives
ES2227519T3 (es) 1992-07-28 2005-04-01 Aventis Pharma Limited Inhibidores de c-amp-fosfodiesterasa.
CA2140440A1 (en) 1992-08-06 1994-02-17 Ellen M. Dobrusin 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
JP3119758B2 (ja) * 1993-02-24 2000-12-25 日清製粉株式会社 7−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
WO1995028926A1 (en) 1994-04-21 1995-11-02 Schering Aktiengesellschaft Pde iv inhibitors for treating multiple sclerosis
GB9420521D0 (en) * 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
JPH09169665A (ja) 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤
JP3601898B2 (ja) 1996-02-14 2004-12-15 俊隆 鍋島 薬物依存形成抑制剤
AUPO282996A0 (en) * 1996-10-07 1996-10-31 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
CA2366615A1 (en) * 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
AU2175302A (en) 2002-05-06
NO20031722D0 (no) 2003-04-14
US20040106641A1 (en) 2004-06-03
HUP0303034A2 (hu) 2003-12-29
NZ525369A (en) 2004-09-24
KR100837099B1 (ko) 2008-06-13
CA2428468C (en) 2011-06-14
US20080207680A1 (en) 2008-08-28
BR0114903A (pt) 2003-10-14
CN1484644A (zh) 2004-03-24
EP1330455A1 (de) 2003-07-30
US7169787B2 (en) 2007-01-30
BG66169B1 (bg) 2011-10-31
PL213999B1 (pl) 2013-06-28
CA2428468A1 (en) 2002-05-02
MXPA03003624A (es) 2004-12-02
WO2002034747A1 (de) 2002-05-02
SK5092003A3 (en) 2004-08-03
SK287774B6 (sk) 2011-09-05
US7419987B2 (en) 2008-09-02
KR100880586B1 (ko) 2009-01-30
AU2002221753B2 (en) 2006-12-14
EE05271B1 (et) 2010-02-15
HUP0303034A3 (en) 2012-12-28
PL362837A1 (en) 2004-11-02
CZ20031146A3 (cs) 2003-10-15
HK1053839A1 (en) 2003-11-07
CN1247576C (zh) 2006-03-29
BG107725A (bg) 2004-08-31
JP2004512337A (ja) 2004-04-22
TWI262920B (en) 2006-10-01
US20060258700A1 (en) 2006-11-16
KR20030065499A (ko) 2003-08-06
AR034269A1 (es) 2004-02-18
HRP20030427B1 (en) 2006-04-30
EP1330455B1 (de) 2005-08-03
PT1330455E (pt) 2005-10-31
EE200300166A (et) 2003-08-15
IL155386A (en) 2008-06-05
DE50106993D1 (de) 2005-09-08
NO20031722L (no) 2003-04-14
NO324947B1 (no) 2008-01-07
IL155386A0 (en) 2003-11-23
ES2246349T3 (es) 2006-02-16
HRP20030427A2 (en) 2003-08-31
KR20080016758A (ko) 2008-02-21
ATE301121T1 (de) 2005-08-15
US7683074B2 (en) 2010-03-23
JP4233322B2 (ja) 2009-03-04

Similar Documents

Publication Publication Date Title
DK1076657T3 (da) Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
DK1443925T3 (da) Naphthyridinderivater, deres fremstilling og deres anvendelse som inhibitorer af phosphodiesteraseisoenzym 4 (PDE4)
DK1373224T3 (da) Nye spirotricykliske derivater og deres anvendelse som phosphodiesterase 7 inhibitorer
DK1425014T3 (da) Diarylcycloalkylderivater, fremgangsmåde til deres fremstilling og deres anvendelse som PPAR-aktivatorer
DK1581532T3 (da) Pyrazolo-3,4-B pyridinforbindelser og deres anvendelse som phosphodiesterase inhibitorer
NO20026010L (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
DK1320531T3 (da) Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
IL152873A0 (en) beta-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE
DK1347955T3 (da) Nye mandelsyrederivater og deres anvendelse som throbin-hæmmere
DK1202733T3 (da) 3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler
NO20032733L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
NO20033288D0 (no) Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer
NO20032830D0 (no) Tetrahydropyridinderivater, fremstilling derav og anvendelse som celle-proliferasjonsinhibitorer
NO20034324D0 (no) Bipiperidinylderivater og deres anvendelse som kjemokin reseptorinhibitor
DK0950657T3 (da) Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
NO20031722D0 (no) Nye 7-azaindoler, anvendelse av de samme som fosfodiesterase- 4-inhibitorerog fremgangsmåte for fremstilling av de samme
NO20040210L (no) Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
DK1255757T3 (da) Aminosyreforbindelser og deres anvendelse som inhibitorer for NEP, ACE og ECE
NO20025884D0 (no) 2-aminotiazolinderivater og deres anvendelse som NO- syntaseinhibitorer
DK1341758T3 (da) Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
NO20033965L (no) Caloporosidderivater, fremgangsmåte for deres fremstilling og deres anvendelse